Home|Journals|Articles by Year|Audio Abstracts
 

Review Article



Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach

Kapil Kumar Garg, S N Chugh.




Abstract

Type 2 diabetes mellitus (T2DM) remains uncontrolled in a large number of patients despite advances in medical treatment. Bromocriptine mesylate is a quick release preparation of bromocriptine, which acts on hypothalamic pathways of glucose metabolism. It represents a novel therapeutic option in the management of T2DM. United States Food and Drug Administration in 2009 approved the use of bromocriptine mesylate in T2DM as an adjunct to diet and exercise. Various clinical trials have demonstrated the efficacy of bromocriptine mesylate in lowering glycosylated hemoglobin by 0.4 to 0.8% as monotherapy or add-on therapy with other antidiabetic agents. Action on central pathways affecting glucose metabolism makes it a great alternative to current modalities of treatment for T2DM.

Key words: Bromocriptine; Dopamine Agonists; Diabetes; Insulin Resistance






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.